Fasudil is under clinical development by Asahi Kasei Pharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Fasudil’s likelihood of approval (LoA) and phase transition for Dementia took place on 12 Jul 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Fasudil Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Fasudil overview

Fasudil (Eril) is a vasodilator agent. It was formulated as injectable solution and powder for solution for intravenous route of administration. Eril is indicated for the improvement of cerebral ischemic symptoms accompanying the cerebral vasospasm and its subarachnoid hemorrhage surgery.

AT-877 (fasudil) is under development for the treatment of amyotropic lateral sclerosis, frontemporal dementia, progressive supranuclear palsy, corticobasal degeneration and Huntington's disease. It was also under development for pulmonary arterial hypertension, acute cerebral infarction, angina pectoris, atherosclerosis and spinal cord injury.

Asahi Kasei Pharma overview

Asahi Kasei Pharma, a subsidiary of Asahi Kasei Corp, manufactures and markets diagnostic reagents, prescription drugs, and enzymes for diagnostic reagents. Its prescription drugs are used in the treatment of osteoporosis pain, disseminated intravascular coagulation, bone loss, dysuria accompanying benign prostatic hyperplasia, nocturia, proteinuria in nephrotic syndrome, and lupus nephritis, among others. Asahi Kasei Pharma offers assay kits for glycemic control and to detect prediabetes. The company’s pipeline products are intended for the treatment of chemotherapy-induced peripheral neuropathy, osteoporosis with high risk of fracture, Lupus nephritis and nephrotic syndrome, and severe sepsis with coagulopathy, among others. It has facilities in Shizuoka, and Nagoya, Japan. Asahi Kasei Pharma is headquartered in Tokyo, Japan.

Quick View Fasudil LOA Data

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Fasudil
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
Key Developers
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.